You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Maverick instrument enables calibration-free multiplex testing in the field and is supported by cloud-based software.
The PCR test detects SARS-CoV-2, influenza A/B, and respiratory syncytial virus type A and B and runs on the Elite InGenius platform and other major thermcyclers.
Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.
The assay should have a CE-IVD mark by November and will serve the Finnish molecular diagnostics firm's growing European client base.
Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.
Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.
LGC will be Swift's worldwide partner for amplicon-based targeted sequencing assays for genotyping AgBio samples, including crop species and animals.
The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.